BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Olga L
OL
Bohn
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Katharine
K
Hsu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
David M
DM
Hyman
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Daniela S
DS
Pignataro
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Sergio
S
Giralt
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: feldstej@mskcc.org.
Julie
J
Teruya-Feldstein
D019943:Amino Acid Substitution; D002454:Cell Differentiation / Q000235:genetics*; D060965:Clonal Evolution; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D009154:Mutation; D009364:Neoplasm Recurrence, Local; D010950:Plasma Cells / Q000378:metabolism* / Q000473:pathology; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics* / Q000378:metabolism
C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
BRAF mutation; Multiple myeloma; Refractory; Relapse; Vemurafenib